Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Spratlin

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Investigational New Drugs|May 5, 2018
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinomaArthur Lui, Karen Mulder, Christine Brezden-Masley, et al.
Investigational New Drugs|December 31, 2015
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancersElizabeth R Kessler, S Gail Eckhardt, Todd M Pitts, et al.
Journal of Clinical Pharmacology|June 23, 2015
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancerKim N Chi, Jennifer Spratlin, Christian Kollmannsberger, et al.
Journal for Immunotherapy of Cancer|October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer|March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
JAMA Oncology|October 14, 2016
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical TrialMichael P Chu, J Randolph Hecht, Dennis Slamon, et al.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Investigational New Drugs|May 5, 2018
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinomaArthur Lui, Karen Mulder, Christine Brezden-Masley, et al.
Investigational New Drugs|December 31, 2015
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancersElizabeth R Kessler, S Gail Eckhardt, Todd M Pitts, et al.
Journal of Clinical Pharmacology|June 23, 2015
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancerKim N Chi, Jennifer Spratlin, Christian Kollmannsberger, et al.
Journal for Immunotherapy of Cancer|October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer|March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
JAMA Oncology|October 14, 2016
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical TrialMichael P Chu, J Randolph Hecht, Dennis Slamon, et al.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Pageof 3